Clinical Trials
Leadership Program
About
Featured ModuleArchived Modules
Module 1-3Week of Oct 27, 2026

Partner engagement and early feasibility

Strengthen your trial question through partner input and early feasibility assessment.

Primary ContentModule 1-3
ThemePartner engagementDuration10 minutes

Learn how early feasibility assessment and meaningful partner engagement can turn an initial idea into a clear, relevant, and workable research question. This module explores who to involve, levels of engagement, and how partner feedback can strengthen question development for both explanatory and pragmatic trials.

Key points

  • Why early partner input matters
  • Choose an appropriate level of engagement, beyond simply informing.
  • Include partners with relevant lived experience, clinical knowledge, and operational expertise.
  • Assess early feasibility before finalizing the question.
Watch on YouTube ↗
ThemeTrial NavigatorDuration2 minutes

Trial Protocol Navigator: Patient and Public Involvement Planning

Learn how to create a Patient and Public Involvement Plan in Trial Protocol Navigator. This two-minute tutorial shows you where to find the section, explore potential partner groups, and document their planned involvement.

Follow the walkthrough to describe your shared approach, support arrangements, accessibility, and compensation. See how to add partner records, select involvement statuses, define roles and contributions, and record optional notes. The video also covers what to document when involvement is not planned and how to open the built-in example for practical guidance.

Watch on YouTube ↗
Learning Activity

Prepare for Your Biweekly Session

  • Read the paper below discussing barriers and facilitators to implementing the MyTEMP trial intervention.
  • Consider your own trial: what feasibility challenges could early partner input help you identify and address?

The facilitator may invite any learner to explain their responses.

First page of Barriers and facilitators to healthcare professional behaviour change in clinical trials using the Theoretical Domains Framework: a case study of a trial of individualized temperature-reduced haemodialysis↗

Barriers and facilitators to healthcare professional behaviour change in clinical trials using the Theoretical Domains Framework: a case study of a trial of individualized temperature-reduced haemodialysis

Presseau et al. Trials (2017) 18:227. DOI: 10.1186/s13063-017-1965-9.

Abstract

Background: Implementing the treatment arm of a clinical trial often requires changes to healthcare practices. Barriers to such changes may undermine the delivery of the treatment making it more likely that the trial will demonstrate no treatment effect. The ‘Major outcomes with personalized dialysate temperature’ (MyTEMP) is a cluster-randomised trial to be conducted in 84 haemodialysis centres across Ontario, Canada to investigate whether there is a difference in major outcomes with an individualized dialysis temperature (IDT) of 0.5 °C below a patient’s body temperature measured at the beginning of each haemodialysis session, compared to a standard dialysis temperature of 36.5 °C. To inform how to deploy the IDT across many haemodialysis centres, we assessed haemodialysis physicians’ and nurses’ perceived barriers and enablers to IDT use.

Methods: We developed two topic guides using the Theoretical Domains Framework (TDF) to assess perceived barriers and enablers to IDT ordering and IDT setting (physician and nurse behaviours, respectively). We recruited a purposive sample of haemodialysis physicians and nurses from across Ontario and conducted in-person or telephone interviews. We used directed content analysis to double-code transcribed utterances into TDF domains, and inductive thematic analysis to develop themes.

Results: We interviewed nine physicians and nine nurses from 11 Ontario haemodialysis centres. We identified seven themes of potential barriers and facilitators to implementing IDTs: (1) awareness of clinical guidelines and how IDT fits with local policies (knowledge; goals), (2) benefits and motivation to use IDT (beliefs about consequences; optimism; reinforcement; intention; goals), (3) alignment of IDTs with usual practice and roles (social/professional role and identity; nature of the behaviour; beliefs about capabilities), (4) thermometer availability/accuracy and dialysis machine characteristics (environmental context and resources), (5) impact on workload (beliefs about consequences; beliefs about capabilities), (6) patient comfort (behavioural regulation; beliefs about consequences; emotion), and (7) forgetting to prescribe or set IDT (memory, attention, decision making processes; emotion).

Conclusions: There are anticipatable barriers to changing healthcare professionals’ behaviours to effectively deliver an intervention within a randomised clinical trial. A behaviour change framework can help to systematically identify such barriers to inform better delivery and evaluation of the treatment, therefore potentially increasing the fidelity of the intervention to increase the internal validity of the trial. These findings will be used to optimise the delivery of IDT in the MyTEMP trial and demonstrate how this approach can be used to plan intervention delivery in other clinical trials.

Trial registration: ClinicalTrials.gov NCT02628366. Registered November 16 2015.

Open paper (PDF) ↗
Clinical Trials Leadership ProgramWestern University · London, Ontario
trialservices@uwo.ca